Experimental cell therapy targets End-Stage heart disease

NCT ID NCT06902896

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This early-stage trial tested a new cell therapy called CAR-DC in 8 people with end-stage dilated cardiomyopathy, a condition that weakens the heart. The therapy targets a protein called FAP to calm the immune system and improve heart function. The main goal was to check safety, with secondary measures looking at changes in the heart's pumping ability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FAP-targeted immunosuppressive CAR-DC cells
What this could lead to: If it works, this could point toward a new cell therapy to control heart failure in end-stage dilated cardiomyopathy.
What could go wrong: This is a very early Phase 1 trial with only 8 people. It primarily tests safety, not effectiveness, and may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY (DCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DILATED CARDIOMYOPATHY (DCM) HEART FAILURE

Contacts and locations

Locations

Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.